tablets "Mitren" are applied at treatment of endometriosis.

Structure

Active ingredient - diyenogest (one tablet contains the diyenogest 2 mg).

Excipients: lactose, monohydrate; corn starch; K-30 povidone; magnesium stearate.

Contraindication

Drug "Mitren" should not be used in the presence of any of following states or diseases. This information is partially obtained on the basis of use of other medicines containing only progestogen. If any of these states or diseases arises for the first time during use of the medicine "Mitren", its reception should be stopped immediately.

1. Venous thrombembolia in an active form.
2. Arterial or cardiovascular diseases in the anamnesis (for example a myocardial infarction, a cerebrovascular event, coronary heart disease).
3. Diabetes with defeat of vessels.
4. Serious illness of a liver now or their existence in the anamnesis until indicators of function of a liver return to norm.
5. Tumour of a liver in the anamnesis (benign or malignant).
6. Known or expected malignant tumors dependent on sex hormones.
7. Vaginal bleeding of not clear etiology.
8. Hypersensitivity to active ingredient or to any of medicine components.

Route of administration

For oral administration.

on one tablet daily without interruption in administration of medicament approximately at the same time, washing down with a small amount of liquid. A pill can be taken irrespective of meal.

should take the Pill regularly, irrespective of menstrual bleeding. As soon as tablets from one packing ended, to begin to take a pill from the following packing, without taking a break in use of medicine.

does not have experience of treatment diyenogesty patients with endometriosis longer than 15 months.

in any day of a menstrual cycle.

Use of any hormonal contraceptives should be stopped prior to therapy by the medicine "Mitren". If contraception is necessary, it is necessary to apply in addition a non-hormonal method of prevention of pregnancy (for example a barrier method).

Feature of application

Pregnant

Mitren is not recommended to be applied to pregnant women as there is no need to treat endometriosis during pregnancy.

.

On the basis of the available data that during treatment diyenogesty at most of patients the ovulation is inhibited. However the medicine "Mitren" is not contraceptive. If contraception is necessary, it is necessary to apply a non-hormonal method of prevention of pregnancy in addition. On the basis of the available data it is possible to claim that the menstrual cycle returns to norm within 2 months after the treatment termination diyenogesty.

by

for application for children before menarche. There are data on efficiency of the diyenogest at treatment of the endometriosis associated with pelvic pain at teenagers (12-18 years) with the general favorable profile of safety and tolerance of medicine. The doctor should weigh advantages of application of the diyenogest and possible risks of application to each teenager.

Drivers

did not observe influence on ability to steer motor transport and to operate mechanisms at patients who took the medicaments containing diyenogest.

Overdose

Research of acute toxicity, carried out with diyenogesty, did not point out risk of development of acute side reactions in case of inadvertent reception of several daily therapeutic doses. No specific antidotes exist. Use of 20-30 mg of the diyenogest to day (that is 10-15 times higher, than a dose in a tablet of the medicine "Mitren") within more than 24 weeks were transferred very well.

Side effects

Side reactions most often develop within the first months of application of the diyenogest and disappear in the course of treatment. Changes of nature of bleedings, such as bloody discharges, irregular bleedings or amenorrhea can be observed.

By-effects about most of which often reported during treatment diyenogesty include a headache (9.0%), discomfort in mammary glands (5.4%), suppressed mood (5.1%) and an acne (5.1%).

to Store

in original packing at a temperature not above 25 °C, out of children's reach.

Expiration date - 3 years.